TITLE

SWOT Analysis

PUB. DATE
August 2007
SOURCE
Shire Pharmaceuticals Group, PLC SWOT Analysis;Aug2007, p5
SOURCE TYPE
SWOT Analysis
DOC. TYPE
Company Report
ABSTRACT
A business analysis of Shire Pharmaceuticals Group PLC, a global specialty pharmaceutical company, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include product portfolio. Weaknesses include increasing SG&A expenses. Opportunities for improvement include acquisition of New River. Threats to the company include patent infringement.
ACCESSION #
26859942

 

Related Articles

  • SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Mar2006, p5 

    Provides a business analysis of Shire Pharmaceuticals Group PLC, a global specialty pharmaceutical company with a strategic focus on developing and marketing products in the areas of central nervous system, gastrointestinal and renal diseases, focusing on its strengths, weaknesses, opportunities...

  • SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Sep2005, p5 

    Provides a business analysis of Shire Pharmaceuticals Group PLC, a global specialty pharmaceutical company with a strategic focus on developing and marketing products in the areas of central nervous system, gastrointestinal and renal diseases, focusing on its strengths, weaknesses, opportunities...

  • Company Overview.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Feb2006, p4 

    Presents an overview of Shire Pharmaceuticals Group PLC, a Basingstoke, England-based global specialty pharmaceutical company. Revenues generated in fiscal year 2004; Principal businesses, including development and marketing of drugs in the areas of central nervous system, gastrointestinal and...

  • SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Feb2007, p5 

    A business analysis of Shire Pharmaceuticals Group PLC, which develops and markets pharmaceutical products in the four therapeutic areas of central nervous system, gastro-intestinal, human genetic therapies and general products, is provided, focusing on its strengths, weaknesses, opportunities...

  • SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Jun2007, p5 

    A business analysis of Shire Pharmaceuticals Group PLC, which develops and markets pharmaceutical products, is provided, focusing on its strengths, weaknesses, opportunities for improvement and threats to the company. Strengths include strong research and development base. Weaknesses include...

  • Shire Pharmaceuticals Group, PLC SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Mar2008, p1 

    A company profile of Shire Pharmaceuticals Group PLC, a company that develops and markets pharmaceutical products, is presented. An overview of the company is given, along with key facts including contact information, number of employees and revenues. A SWOT analysis is provided which includes...

  • DATAMONITOR: Shire plc.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;Apr2010, p1 

    A company profile of Shire Pharmaceuticals Group PLC, which is a global specialty biopharmaceutical company, is presented. An overview of the company is given, along with key facts including contact information, number of employees and revenues. A SWOT analysis is provided which includes...

  • Shire Pharmaceuticals Group, PLC SWOT Analysis.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;August 2003, p1 

    Presents an overview of Shire Pharmaceuticals Group PLC, a pharmaceutical company which focuses on four therapeutic areas, namely central nervous system disorders, gastrointestinal, oncology and anti-infectives. Company overview, including revenues generated in fiscal year 2002 and location of...

  • Company Overview.  // Shire Pharmaceuticals Group, PLC SWOT Analysis;August 2003, p4 

    Presents an overview of Shire Pharmaceuticals Group PLC, a pharmaceutical company which focuses on four therapeutic areas, namely central nervous system disorders, gastrointestinal, oncology and anti-infectives. Revenues generated in fiscal year 2002; Location of the company's headquarters.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics